Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
153.6 USD | +3.38% | +18.58% | -14.85% |
04-23 | Sector Update: Health Care Stocks Rise in Afternoon Trading | MT |
04-23 | BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise | MT |
Sales 2024 * | 3.08B 4.21B | Sales 2025 * | 3.92B 5.36B | Capitalization | 16.05B 21.94B |
---|---|---|---|---|---|
Net income 2024 * | -892M -1.22B | Net income 2025 * | -356M -487M | EV / Sales 2024 * | 4.72 x |
Net cash position 2024 * | 1.48B 2.03B | Net cash position 2025 * | 1.13B 1.55B | EV / Sales 2025 * | 3.8 x |
P/E ratio 2024 * |
-18
x | P/E ratio 2025 * |
-42.3
x | Employees | 10,600 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.21% |
Latest transcript on BeiGene, Ltd.
1 day | +3.38% | ||
1 week | +18.58% | ||
Current month | -1.80% | ||
1 month | -0.15% | ||
3 months | -5.14% | ||
6 months | -7.40% | ||
Current year | -14.85% |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.48% | 4 M€ | -27.92% | ||
1.49% | 0 M€ | 0.00% | - | |
1.39% | 9 M€ | -4.31% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 153.6 | +3.38% | 208,460 |
24-04-25 | 148.6 | +3.08% | 409,342 |
24-04-24 | 144.1 | +3.69% | 215,690 |
24-04-23 | 139 | +6.15% | 203,615 |
24-04-22 | 130.9 | +1.10% | 152,563 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.85% | 16.05B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
+3.21% | 13.68B | |
+33.54% | 12.17B | |
-24.71% | 8.24B |
- Stock Market
- Equities
- BGNE Stock